This work was funded by the U.S. Army Medical Research and Medical Command (grant: F_025_2010_USAISR) awarded to T.J.W., and National Institutes of Health grant awarded to J.M. All animal protocols were approved by the U.S. Army Institute of Surgical Research Animal Care and Use Committee. This study adhered to National Institutes of Health guidelines for the care and use of laboratory animals (DHHS Publication, NIH, 86 to 23). All components of this study including the decision where to publish were at the sole discretion of the authors. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the Department of Defense (AR 360-5) or the United States Government. Some of the authors are employees of the U.S. government, and this work was prepared as part of their official duties.
Effect of recombinant human MG53 protein on tourniquet-induced ischemia-reperfusion injury in rat muscle
Version of Record online: 17 MAY 2014
Published 2014 by Wiley Periodicals, Inc. This article is a US Government work and, as such, is in the public domain in the United States of America.
Muscle & Nerve
Volume 49, Issue 6, pages 919–921, June 2014
How to Cite
Corona, B. T., Garg, K., Roe, J. L., Zhu, H., Park, K. H., Ma, J. and Walters, T. J. (2014), Effect of recombinant human MG53 protein on tourniquet-induced ischemia-reperfusion injury in rat muscle. Muscle Nerve, 49: 919–921. doi: 10.1002/mus.24160
- Issue online: 17 MAY 2014
- Version of Record online: 17 MAY 2014
- Accepted manuscript online: 3 JAN 2014 01:10AM EST
- Manuscript Accepted: 30 DEC 2013
Additional Supporting Information may be found in the online version of this article.
|mus24160-sup-0001-suppfig1.tif||5355K||SUPPLEMENTAL FIGURE S1. A–D: H&E sections in Fig. 1 were semiquantitatively analyzed by a veterinary pathologist. Means are illustrated by the horizontal line in each plot. E: The 30 μg rhMG53 protein was stained on a membrane with Ponceau after gel electrophoresis. Note the large band at ∼53 kDa, indicating that the rhMG53 protein used in this study was not degraded prior to use. F: The rhMG53 administration improved C2C12 myotube viability in vitro after H2O2 exposure; values are means ± SEM, n = 3 per group.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.